Unpacking the Latest Options Trading Trends in Pfizer

Investors with a lot of money to spend have taken a bearish stance on Pfizer PFE.

And retail traders should know.

We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PFE, it often means somebody knows something is about to happen.

Today, Benzinga's options scanner spotted 9 options trades for Pfizer.

This isn't normal.

The overall sentiment of these big-money traders is split between 33% bullish and 66%, bearish.

Out of all of the options we uncovered, there was 1 put, for a total amount of $28,000, and 8, calls, for a total amount of $261,520.

What's The Price Target?

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $26.0 to $35.0 for Pfizer over the recent three months.

Volume & Open Interest Trends

Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Pfizer's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Pfizer's whale trades within a strike price range from $26.0 to $35.0 in the last 30 days.

Pfizer Option Activity Analysis: Last 30 Days

Noteworthy Options Activity:

About Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

In light of the recent options history for Pfizer, it's now appropriate to focus on the company itself. We aim to explore its current performance.

Pfizer's Current Market Status

• With a trading volume of 6,128,609, the price of PFE is up by 0.83%, reaching $27.86.
• Current RSI values indicate that the stock is is currently neutral between overbought and oversold.
• Next earnings report is scheduled for 40 days from now.

Professional Analyst Ratings for Pfizer

In the last month, 4 experts released ratings on this stock with an average target price of $33.25.

• Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Pfizer, targeting a price of $36.
• Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Pfizer, targeting a price of $27.
• Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Pfizer with a target price of $28.
• An analyst from Truist Securities has revised its rating downward to Buy, adjusting the price target to $42.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Pfizer, Benzinga Pro gives you real-time options trades alerts.